Published in J Am Soc Nephrol on July 18, 2016
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 4.39
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood (2007) 2.72
IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol (2004) 2.47
TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta (2009) 2.44
TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology (2008) 2.19
C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature (2007) 2.06
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A (2009) 2.04
Microbial hijacking of complement-toll-like receptor crosstalk. Sci Signal (2010) 1.91
Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood (2006) 1.77
The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem (2009) 1.73
Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol (2003) 1.61
Toll-like receptor signaling pathways. Front Immunol (2014) 1.58
Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. BioTechniques 10(4): 506-13 (April 1991). Biotechniques (2013) 1.51
Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J (2003) 1.42
Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol (2001) 1.36
The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol (1994) 1.36
TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med (2008) 1.32
Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol (1999) 1.32
The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization. Immunology (1979) 1.26
Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity (2014) 1.25
Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med (2013) 1.23
Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol (2009) 1.22
Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol (2013) 1.18
Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech (2014) 1.16
TLR based therapeutics. Curr Opin Pharmacol (2011) 1.10
Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis (2000) 1.08
Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv Exp Med Biol (2008) 1.07
TLR2 mediates recognition of live Staphylococcus epidermidis and clearance of bacteremia. PLoS One (2010) 1.04
Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol (2014) 1.03
Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators Inflamm (2012) 1.00
TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur J Immunol (2011) 1.00
Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta (2012) 0.99
Mechanisms and interventions in peritoneal fibrosis. Clin Exp Nephrol (2011) 0.93
Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrol Dial Transplant (2011) 0.87
The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol (2012) 0.87
Peritoneal morphology in children treated by continuous ambulatory peritoneal dialysis. Pediatr Nephrol (1992) 0.86
Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis. PLoS One (2015) 0.85
Inhibition of caspases improves bacterial clearance in experimental peritonitis. Perit Dial Int (2003) 0.83
Complement activation during CAPD. Nephrol Dial Transplant (1993) 0.81
Morphological aspects of peritoneal sclerosis. J Nephrol (2002) 0.81
The potential role of HMGB1 release in peritoneal dialysis-related peritonitis. PLoS One (2013) 0.81
Complement in serum and dialysate in children on continuous ambulatory peritoneal dialysis. Perit Dial Int (1995) 0.80
Regulation of complement C3 and C4 synthesis in human peritoneal mesothelial cells by peritoneal dialysis fluid. Clin Exp Immunol (2004) 0.80
Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Sci Transl Med (2013) 0.79
Pathophysiology and morphological clinical correlation in experimental and peritoneal dialysis-induced peritoneal sclerosis. Adv Perit Dial (2000) 0.77
Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol (2014) 0.77
Cardiovascular disease in peritoneal dialysis patients. Panminerva Med (2009) 0.77
Clinical applications of crossed immunoelectrophoresis to the study of complement activation. J Clin Lab Immunol (1987) 0.76